Medicxi invests $40m in D3 Bio, enhancing oncology pipeline
Life sciences investment firm Medicxi has injected $40 million in D3 Bio, a biotechnology company based in Shanghai, China.
Archives for April 8, 2024
How are GSK improving outcomes for people with the most prevalent gynaecological cancer in the UK?
GSK's Jemperli (dostarlimab) has been approved for use within NHS Scotland, marking a significant step in the treatment of eligible endometrial cancer patients in the region.
Enrollment completed for trial of drug to treat children with rare primary immunodeficiency
Pharming Group N.V. has declared the successful enrollment completion in its phase 3 clinical trial of leniolisib, an investigational drug designed for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
Interview: Emmes Mindy Leffler - are video based assessments the way forward to evaluate patients at home?
Individuals diagnosed with Duchenne muscular dystrophy (DMD) often develop compensatory movement patterns due to muscle weakening.
Quotient Sciences' Vanessa Zann on the company's fascinating updates in drug development
In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.